CA-125 in Screening Patients at High Risk for Ovarian Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• At high risk for developing ovarian cancer, as determined by meeting criteria for 1 of the following:
• * Family history of at least 2 ovarian or breast\* cancers among the patient and first- and second-degree relatives within the same lineage\*\*
• * If breast cancer\* is required to meet this criterion, at least 1 breast cancer\* must be premenopausal (diagnosed at age 50 or under if menopausal status unknown) NOTE: \*\*Multiple primary cancers in the same person satisfies this criterion
• * Ashkenazi Jewish ethnicity and meets criteria for 1 of the following:
• * Prior breast cancer\* diagnosis
• * One first-degree or 2 second-degree relatives with breast\* or ovarian cancer
• * If breast cancer is required to meet this criterion, at least 1 breast cancer\* must be premenopausal (diagnosed at age 50 or under if menopausal status unknown)
• * Probability of BRCA1 or BRCA2 mutation greater than 20%, as determined by BRCAPRO 95% posterior probability interval
• * This criterion includes the following situations for which BRCAPRO is not required:
• * Tested positive for a BRCA1 or BRCA2 mutation (100% probability)
• * First- or second-degree relative with a BRCA1 or BRCA2 mutation NOTE: \*Including ductal carcinoma in situ
• No ovarian cancer, including low malignant potential cancers or primary papillary serous carcinoma of the peritoneum
• PATIENT CHARACTERISTICS:
• Age
• 30 and over
• Performance status
• Not specified
• Life expectancy
• Not specified
• Hematopoietic
• No hemophilia
• No other bleeding disorders
• Hepatic
• Not specified
• Renal
• Not specified
• Pulmonary
• No emphysema
• Other
• Not pregnant
• Negative pregnancy test
• Fertile patients must use effective contraception
• No psychiatric or psychological condition that would preclude giving informed consent
• No concurrent untreated malignancy except nonmelanoma skin cancer
• No other medical condition that would preclude blood draws (e.g., chronic infectious disease)
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Not specified
• Chemotherapy
• More than 3 months since prior adjuvant chemotherapy for cancer
• Endocrine therapy
• Concurrent adjuvant hormonal therapy (e.g., tamoxifen, leuprolide, or goserelin) allowed
• Radiotherapy
• More than 3 months since prior adjuvant radiotherapy for cancer
• Surgery
• More than 3 months since prior intraperitoneal surgery (laparoscopy or laparotomy)
• Prior prophylactic oophorectomy allowed
• Other
• More than 5 years since prior treatment (excluding hormonal therapy) for metastatic malignancy
• No concurrent participation in other ovarian cancer early detection trials